中药联合长春瑞滨治疗46例老年ⅢB/Ⅳ期非小细胞肺癌  

Results of combination therapy with xiaoji decoction/Huachansu and vinorelbine in elderly advanced non- small cell lung cancer

作　　者：吴万垠[1] 柴小姝[1] 李新[1] 张海波[1] 邓宏[1] 龙顺钦[1] 刘伟胜[1] 

机构地区：[1]广东省中医院芳村分院肿瘤科,广州510370

出　　处：《癌症进展》2007年第5期425-430,共6页Oncology Progress

摘　　要：目的观察消积饮、华蟾素联合长春瑞滨对老年ⅢB/Ⅳ期非小细胞肺癌的疗效和毒副作用。方法给予46例老年ⅢB/Ⅳ期非小细胞肺癌患者消积饮30ml/m^2,po,bid×21d;华蟾素20ml/m^2,静滴(iv),qd×10d;长春瑞滨30ml/m^2,iv,d1,8,21天为1个周期,连续治疗4个周期。观察治疗前后瘤体变化、PS评分变化、中位生存时间、1年生存率、疾病无进展时间以及毒副作用。结果符合纳入标准的46名患者平均给予治疗3.2个周期。该研究总有效率(CR+PR)为19.6%,稳定率(CR+PR+NC)为89.1%,中位生存期(MST)为7.5个月,1年生存率为28.3%,疾病无进展时间(TTP)为5.2个月。该方案的主要毒副作用为骨髓抑制,12例出现白细胞下降,2例Ⅲ度疲劳,4例出现肝功能损害,4例出现Ⅰ度神经毒性。结论消积饮、华蟾素联合长春瑞滨的中西医结合治疗方案可提高患者总体生存质量,且毒副作用微弱,更适合作为老年晚期非小细胞肺癌患者的中西医结合治疗方案。Objective To observe the chansu/Vinorelbine againet older stage Ⅲ B/ cording to integration and exclusion standard, therapeutic efficacy and tocitity of Xiaoji -decoction/Hua-Ⅳ non-small cell lung cancer （NSCLC）. Methods Acthis method requires to select stage Ⅲ B/Ⅳ non-small cell lung cancer elder patients who enrolled from January. 2000 to March 2006 and have a EGCO performance status of 0 -2. They received Xiaoji - decoction, Hua Chansu unite Vinorelbine. Finally, we evaluate the reinvestigation of changing tumor size, 1-year survival rate, median survival time, and toxicity. Resuits Totally 54 eligible patients with stage m B/tv NSCLC received the first treatment. Nine patients （19.6%） had partial response, 32 （89.1%） had stable disease and 5 （ 10. 9% ） underwent progressive disease. By Kaplan - Meier survival analysis, the median time to disease Wogression was 5.2 months and the median survival was 7.5 months. The 1-year survival rate was 28.3%. Most symptoms resolved after the treatment. PS scores and the quality of life improved after the therapy. The major toxicity was myelosuppression. ity in elderly Conclusions This combination regimen has preliminary therapeutic efficacy and mild toxicpatients with advanced NSCLC and suitable for further clinical trial

关 键 词：中药 长春瑞滨 老年 晚期 非小细胞肺癌 

分 类 号：R730.59[医药卫生—肿瘤]